Role of dipeptidyl peptidase-4 inhibitors in patients with diabetes infected with coronavirus-19

Chun Fan Chen; Chian Hsu Chien; Yi Ping Yang; Shih Jie Chou; Mong Lien Wang; The Ia Huo; Chih Ching Lin

doi:10.1097/JCMA.0000000000000338

Role of dipeptidyl peptidase-4 inhibitors in patients with diabetes infected with coronavirus-19

Chun Fan Chen, Chian Hsu Chien, Yi Ping Yang, Shih Jie Chou, Mong Lien Wang, The Ia Huo, Chih Ching Lin^*

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

15 Scopus citations

Abstract

The pandemic infection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is widely increasing the patients affiliated with coronavirus disease 2019 (COVID-19) from last December of 2019. It is reported that the entry receptor of SARS-CoV-2 has been confirmed to be angiotensin-converting enzyme 2 (ACE2). Notably, whether the ACE-related inhibitors or drugs modulated ACE2 activity in affecting the viral activity and disease severity of SARS-CoV-2 is still an open question. Dipeptidyl peptidase-4 (DDP-4), a well-known anti-diabetic drug, has been widely used to control the glycemic condition in patients with diabetes. In this article, we are focusing on the impact of ACE inhibitors (ACEI) and DPP4 inhibitors used on SARS-CoV-2 activity and discussions about those drugs that may be related to infectious condition of COVID-19 diseases.

Original language	English
Pages (from-to)	710-711
Number of pages	2
Journal	Journal of the Chinese Medical Association
Volume	83
Issue number	8
DOIs	https://doi.org/10.1097/JCMA.0000000000000338
State	Published - Aug 2020

Keywords

Coronavirus disease 2019
Dipeptidyl peptidase-4 inhibitors
Severe acute respiratory syndrome coronavirus 2

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1097/JCMA.0000000000000338

Cite this

@article{62fe77c56c3d4219bdfdf7267e449c50,

title = "Role of dipeptidyl peptidase-4 inhibitors in patients with diabetes infected with coronavirus-19",

abstract = "The pandemic infection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is widely increasing the patients affiliated with coronavirus disease 2019 (COVID-19) from last December of 2019. It is reported that the entry receptor of SARS-CoV-2 has been confirmed to be angiotensin-converting enzyme 2 (ACE2). Notably, whether the ACE-related inhibitors or drugs modulated ACE2 activity in affecting the viral activity and disease severity of SARS-CoV-2 is still an open question. Dipeptidyl peptidase-4 (DDP-4), a well-known anti-diabetic drug, has been widely used to control the glycemic condition in patients with diabetes. In this article, we are focusing on the impact of ACE inhibitors (ACEI) and DPP4 inhibitors used on SARS-CoV-2 activity and discussions about those drugs that may be related to infectious condition of COVID-19 diseases.",

keywords = "Coronavirus disease 2019, Dipeptidyl peptidase-4 inhibitors, Severe acute respiratory syndrome coronavirus 2",

author = "Chen, {Chun Fan} and Chien, {Chian Hsu} and Yang, {Yi Ping} and Chou, {Shih Jie} and Wang, {Mong Lien} and Huo, {The Ia} and Lin, {Chih Ching}",

note = "Publisher Copyright: Copyright {\textcopyright} 2020, the Chinese Medical Association.",

year = "2020",

month = aug,

doi = "10.1097/JCMA.0000000000000338",

language = "English",

volume = "83",

pages = "710--711",

journal = "Journal of the Chinese Medical Association",

issn = "1726-4901",

publisher = "Elsevier Taiwan LLC",

number = "8",

}

TY - JOUR

T1 - Role of dipeptidyl peptidase-4 inhibitors in patients with diabetes infected with coronavirus-19

AU - Chen, Chun Fan

AU - Chien, Chian Hsu

AU - Yang, Yi Ping

AU - Chou, Shih Jie

AU - Wang, Mong Lien

AU - Huo, The Ia

AU - Lin, Chih Ching

PY - 2020/8

Y1 - 2020/8

N2 - The pandemic infection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is widely increasing the patients affiliated with coronavirus disease 2019 (COVID-19) from last December of 2019. It is reported that the entry receptor of SARS-CoV-2 has been confirmed to be angiotensin-converting enzyme 2 (ACE2). Notably, whether the ACE-related inhibitors or drugs modulated ACE2 activity in affecting the viral activity and disease severity of SARS-CoV-2 is still an open question. Dipeptidyl peptidase-4 (DDP-4), a well-known anti-diabetic drug, has been widely used to control the glycemic condition in patients with diabetes. In this article, we are focusing on the impact of ACE inhibitors (ACEI) and DPP4 inhibitors used on SARS-CoV-2 activity and discussions about those drugs that may be related to infectious condition of COVID-19 diseases.

AB - The pandemic infection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is widely increasing the patients affiliated with coronavirus disease 2019 (COVID-19) from last December of 2019. It is reported that the entry receptor of SARS-CoV-2 has been confirmed to be angiotensin-converting enzyme 2 (ACE2). Notably, whether the ACE-related inhibitors or drugs modulated ACE2 activity in affecting the viral activity and disease severity of SARS-CoV-2 is still an open question. Dipeptidyl peptidase-4 (DDP-4), a well-known anti-diabetic drug, has been widely used to control the glycemic condition in patients with diabetes. In this article, we are focusing on the impact of ACE inhibitors (ACEI) and DPP4 inhibitors used on SARS-CoV-2 activity and discussions about those drugs that may be related to infectious condition of COVID-19 diseases.

KW - Coronavirus disease 2019

KW - Dipeptidyl peptidase-4 inhibitors

KW - Severe acute respiratory syndrome coronavirus 2

UR - http://www.scopus.com/inward/record.url?scp=85084617438&partnerID=8YFLogxK

U2 - 10.1097/JCMA.0000000000000338

DO - 10.1097/JCMA.0000000000000338

M3 - Review article

C2 - 32349031

AN - SCOPUS:85084617438

SN - 1726-4901

VL - 83

SP - 710

EP - 711

JO - Journal of the Chinese Medical Association

JF - Journal of the Chinese Medical Association

IS - 8

ER -

Role of dipeptidyl peptidase-4 inhibitors in patients with diabetes infected with coronavirus-19

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this